Search results
Showing 51 to 100 of 663 results for diabetes
This indicator covers the proportion of children and young people aged under 18 years with type 1 diabetes who have had their BMI recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged under 18 years with type 2 diabetes who have had their glycated haemoglobin A1c (HbA1c) monitored in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged under 18 years with type 1 diabetes who have had their glycated haemoglobin A1c (HbA1c) monitored in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of eligible people with diabetes who are excluded from diabetic eye screening as they have opted out or are classed as medically unfit. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG90
This indicator covers the proportion of eligible people with diabetes who are suspended from diabetic eye screening due to previous screening results. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG89
This indicator covers the proportion of eligible people with diabetes who have not attended for diabetic eye screening in the previous 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG87
Diabetes: admission rates (renal replacement therapy) (IND45)
This indicator covers admission rates for renal replacement therapy in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG63
This indicator covers the proportion of children and young people aged under 18 years with type 2 diabetes who have had their blood pressure recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Topic prioritisation
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have had their blood pressure recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 58 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM141
This indicator covers admission rates due to lower limb amputations in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG65
Diabetes: thyroid disease screening (children T1DM) (IND312)
This indicator covers the proportion of children and young people aged under 18 years with type 1 diabetes who have been screened for thyroid disease in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the establishing and maintaining of a register of all patients with a diagnosis of non-diabetic hyperglycaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM148
Diabetes: annual psychological assessment (children T2DM) (IND314)
This indicator covers the proportion of children and young people aged under 18 years with type 2 diabetes who have received a psychological assessment in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Diabetes: annual psychological assessment (children T1DM) (IND313)
This indicator covers the proportion of children and young people aged under 18 years with type 1 diabetes who have received a psychological assessment in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM97.
This indicator covers the percentage of patients with non-diabetic hyperglycaemia who have had an HbA1c test or FPG test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM150
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
This indicator covers establishing and maintaining a register of all patients aged 17 or over with diabetes mellitus, which specifies the type of diabetes where a diagnosis has been confirmed. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM41
1 Type 2 diabetes: agreeing my blood glucose (HbA1c) target Patient decision aid c NICE 2022. All rights reserved. Subject to Notice of...
This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.
Diabetes: structured education within 12 months of diagnosis (IND11)
This indicator covers the proportion of adults with diabetes referred to a structured education programme within 12 months of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG14
This indicator covers admission rates due to myocardial infarction in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG60
In development Reference number: GID-NG10450 Expected publication date: TBC
Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)
Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making
Awaiting development Reference number: GID-TA10439 Expected publication date: TBC
Awaiting development Reference number: GID-TA10438 Expected publication date: TBC
Diabetes: lipid-lowering therapies for primary prevention of CVD (40 years and over) (IND275)
This indicator covers the percentage of patients with diabetes aged 40 years and over, with no history of cardiovascular disease and without moderate or severe frailty, who are currently treated with a lipid-lowering therapy (excluding patients with type 2 diabetes and a cardiovascular disease risk score of less than 10% recorded in the preceding 3 years). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Diabetes: lipid-lowering therapies for primary prevention of CVD (T2DM and 10% risk) (IND274)
This indicator covers the percentage of patients with a diagnosis of type 2 diabetes and a recorded cardiovascular disease risk assessment score of 10% or more (without moderate or severe frailty), who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.
This indicator covers admission rates due to heart failure in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG61
This indicator covers the proportion of children and young people aged 12 to 18 years with type 2 diabetes who have a record of eye screening in the previous 24 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have a record of eye screening in the previous 24 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.
This guideline covers routine preoperative tests for people aged over 16 who are having elective surgery. It aims to reduce unnecessary testing by advising which tests to offer people before minor, intermediate and major or complex surgery, taking into account specific comorbidities (cardiovascular, renal and respiratory conditions and diabetes and obesity). It does not cover pregnant women or people having cardiothoracic procedures or neurosurgery.
This indicator covers the percentage of patients with diabetes with a record of testing of foot sensation using a 10 g monofilament within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM131
This indicator covers the percentage of patients with type 1 diabetes aged over 40 years (excluding people with a history of haemorrhagic stroke) who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)
Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making
This indicator covers the proportion of children and young people aged 12 to 18 years with type 2 diabetes who received individual care processes in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who received individual care processes in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged under 18 years with type 2 diabetes who have had their urinary albumin recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 2 diabetes who have had their smoking status recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have had their smoking status recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have had their urinary albumin recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes (HTG371)
Evidence-based recommendations on implantation of a duodenal-jejunal bypass liner for managing type 2 diabetes. This involves attaching a liner as a barrier between food and the upper part of the bowel, with the aim of lowering blood sugar levels.
Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249]
Topic prioritisation